Fibrates for PBC: Bezafibrate and Elafibranor as Second-Line Options
Fibric acid derivatives (fibrates) — a class of drugs primarily used for high triglycerides — have emerged as a promising second-line option for PBC patients who respond inadequately to UDCA. Their mechanism in PBC involves PPARα activation, which reduces bile acid synthesis and improves biliary secretion. Bezafibrate has the longest clinical history. Multiple Japanese studies and the European BEZURSO trial showed bezafibrate combined with UDCA achieved the Paris II biochemical response criteria in 31% of inadequate UDCA responders vs. 0% with placebo, along with significant ALP normalization in some patients. It's not FDA-approved for PBC and is unavailable in the US, but is used off-label in Europe and Asia. The dose studied is 400 mg/day. Elafibranor (Iqirvo) is a next-generation dual PPARα/δ agonist developed specifically for PBC. The ELATIOND Phase 3 trial reported a 51% composite response rate at 52 weeks vs. 19% for placebo — leading to FDA approval in June 2024 as a second-line add-on to UDCA. It's taken as a once-daily 80 mg oral tablet. Unlike obeticholic acid, it doesn't appear to worsen pruritus. Side effects include headache and abdominal pain. It's indicated for adults with inadequate response or intolerance to UDCA, positioning it alongside seladelpar as an alternative second-line choice.
Read original source